ipilimumab
Ligand Summary
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
ChEMBL: CHEMBL1789844
DrugCentral: 4958
LyCHI: ipilimumab
Target Activities
1 Activities
Items per page:
10
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
ANTIBODY BINDING | ||||||